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In Brief
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accumulates in the cells from patients
with peroxisomal disorders.
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SUMMARY
Cholesterol is dynamically transportedamongorgan-
elles, which is essential formultiple cellular functions.
However, the mechanism underlying intracellular
cholesterol transport has remained largely unknown.
We established an amphotericin B-based assay
enabling a genome-wide shRNA screen for delayed
LDL-cholesterol transport and identified 341 hits
with particular enrichment of peroxisome genes,
suggesting a previously unappreciated pathway for
cholesterol transport. We show dynamic membrane
contacts between peroxisome and lysosome, which
are mediated by lysosomal Synaptotagmin VII bind-
ing to the lipid PI(4,5)P2 on peroxisomal membrane.
LDL-cholesterol enhances such contacts, and
cholesterol is transported from lysosome to peroxi-
some. Disruption of critical peroxisome genes leads
to cholesterol accumulation in lysosome. Together,
these findings reveal an unexpected role of peroxi-
some in intracellular cholesterol transport.We further
demonstrate massive cholesterol accumulation in
humanpatient cells andmousemodel of peroxisomal
disorders, suggesting a contribution of abnormal
cholesterol accumulation to these diseases.
INTRODUCTION
Cholesterol, an essential lipid for eukaryotic cells, plays impor-
tant roles in many cellular processes including membrane prop-
erties regulation, steroidogenesis, bile acid synthesis, and signal
transduction. Accounting for 30%–40% of total cellular lipids,
cholesterol is dynamically transported in cells and unevenly
distributed in cellular membrane structures. Only 0.5%–1%
of total cellular cholesterol is present in the ERmembrane (Lange
et al., 1999) and its concentration is higher in the Golgi apparatus
and highest (60%–80%) in the plasmamembrane (PM) (Liscum
and Munn, 1999). In addition, cholesterol exerts diverse cellular
functions in different organelles. Sterols in ER control de novo
cholesterol biosynthesis by inhibiting SREBP processing and
promoting degradation of HMG-CoA reductase (Goldstein
et al., 2006). Cholesterol is esterified in ER for storage and lipo-
protein secretion (Chang et al., 1997; Vance and Vance, 1990)
and oxidized and converted to steroids and bile acids in mito-
chondria and peroxisome (Ishibashi et al., 1996). Thus, dynamic
cholesterol transport in cells is pivotal for multiple cellular
functions.
Low density lipoprotein (LDL)-derived cholesterol trafficking
is a major part of intracellular cholesterol transport with most
mammalian cells acquiring80%of their cholesterol through re-
ceptor-mediated endocytosis of plasma LDL (Brown and Gold-
stein, 1986). Upon receptor binding and internalization, LDL is
delivered from early endosome to late endosome/lysosome
(L/L), where LDL-derived cholesteryl esters are hydrolyzed to un-
esterified cholesterol. Free cholesterol then egresses from L/L
and is further passed to downstream organelles such as the
PM, ER, and mitochondria to fulfill its functions (Chang et al.,
2006). To date, mostmechanistic knowledge on cholesterol pas-
sage from L/L to other organelles has come from studies of the
inheritable neuronal degeneration disorder Niemann Pick type
C (NPC) disease, which is caused by loss-of-function mutations
in NPC1 or NPC2 genes (Carstea et al., 1997; Sleat et al., 2004).
NPC patients show severe cholesterol accumulation in multiple
tissues. NPC1 is a polytopic membrane protein on L/L, whereas
NPC2 is a luminal protein. After cholesteryl ester is hydrolyzed in
the lysosomal lumen, NPC2 binds the unesterified cholesterol by
recognizing the 8-carbon isooctyl side chain. NPC2 then hands
over the cholesterol molecule to the N-terminal domain of
NPC1, with the 3b-hydroxyl group buried within the binding
pocket. The NPC1-bound cholesterol projects through the gly-
cocalyx and is inserted into the lysosomal membrane. In NPC1
or NPC2 mutant cells, cholesterol cannot be incorporated into
membrane and is therefore accumulated in the lumen (Kwon
et al., 2009). However, this only accounts for how free cholesterol
reaches the L/L membrane, and the mechanisms whereby
cholesterol leaves the lysosomal membrane and moves to other
organelles remain largely unknown.
To identify critical proteins for intracellular cholesterol trans-
port, we developed a cellular system using the antifungal
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Figure 1. Genome-wide RNAi Screen Identifies Genes Involved in Intracellular Cholesterol Transport
(A) Schematic representation of the screen strategy.
(B) The cells were treated as shown in (A) and Figure S1C. The PM cholesterol and effect of AmB on cell growth at each time point were determined.
(C) PM cholesterol levels and survival ratio based on crystal violet staining of each selection round. Results represent the mean ± SD of three independent
experiments.
(legend continued on next page)
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antibiotic amphotericin B (AmB), in which cells only survive
when they have impaired intracellular cholesterol transport. We
performed a genome-wide pooled shRNA screen with the AmB
system and identified over 300 genes affecting cholesterol trans-
port. The genes encoding peroxisomal proteins were enriched.
We further demonstrated that peroxisome forms transient lyso-
some-peroxisome membrane contact (LPMC) with lysosome
through the binding of peroxisomal lipid PI(4,5)P2 by lysosomal
protein Synaptotagmin VII (Syt7). Cholesterol can be transported
to peroxisome from lysosome through LPMC. Consistent with
the latter findings, we observed drastic cholesterol accumulation
in the X-chromosomal form of adrenoleukodystrophy (X-ALD)
mouse model and in fibroblasts from human patients with
different types of peroxisomal disorders. Our findings therefore
reveal a fundamental role of peroxisome in intracellular choles-
terol transport and suggest potential novel strategies for the
diagnosis and treatment of peroxisome-related diseases.
RESULTS
Genome-wide Pooled shRNA Screening for Cholesterol
Trafficking Defective Cells
AmB binds to cholesterol in PM and forms pores that lead to
cytoplasm leakage and cell death (Andreoli, 1973). Based on
this property, we designed a genome-wide shRNA screen to
identify genes required for intracellular cholesterol transport, in
particular the transport of cholesterol from LDL receptor
(LDLR)-mediated endocytosis. The rationale and overall process
of the screen are depicted in Figure 1A. There are three key ele-
ments, namely: (1) inhibition of endogenous cholesterol biogen-
esis throughout the entire process and delivery of cholesterol by
LDL particles to focus on the transport of LDL-derived choles-
terol, (2) synchronization of cells at the stage of high cholesterol
in L/L and low cholesterol in PM so that the cholesterol can be
transported to the PM in all cells at a given time point, and (3)
enrichment of cholesterol trafficking defective (CTD) cells by us-
ing AmB that kills the cells with proper cholesterol transport in a
controlled manner. The first key element is achieved by using
lovastatin to inhibit HMG-CoA reductase and low concentration
of mevalonate to only permit the synthesis of nonsterol isopre-
noids essential for cell growth. Lipoprotein-deficient serum is
also used before LDL delivery so that the cells are in cholesterol
starvation and the initial LDLR level is very high. The second key
element is realized by using U18666A, a compound that revers-
ibly blocks cholesterol efflux from L/L (Liscum and Faust, 1989),
and cyclodextrin, a cholesterol mobilizing reagent (Liu et al.,
2010; Rosenbaum et al., 2010). Co-treatment of cholesterol-
starved cells with LDL, lovastatin, and U18666A leads to
LDLR-mediated endocytosis of large amounts of cholesterol
which is trapped in L/L by U18666A. After a short exposure to
cyclodextrin to acutely deplete cholesterol from PM, the cells
are incubated without U18666A to allow cholesterol transport
from L/L to PM. AmB is then used to kill the cells with more
cholesterol in PM. The cholesterol trafficking rate and PM-
cholesterol level are lower in CTD cells than wild-type (WT) cells
at particular time points. Thus, these CTD cells can survive AmB
treatment.
The procedure described above was validated by comparing
WT CHO-7- and NPC1-deficient CT43 cells (Figure 1B). Cyclo-
dextrin decreased the PM-cholesterol level to 0.59 mg/mg
protein. After removal of U18666A, PM-cholesterol level was
much higher in CHO-7 than CT43 cells and the former was
more sensitive to AmB treatment (Figure 1B). To perform the
screen, HeLa cells were infected with a pooled shRNA library
and the virus-infected cells were subjected to AmB selection
as described above (Figure S1A). We observed gradual
decrease of PM-cholesterol and increase of survival rate in the
first five rounds of selection before reaching plateau (Figure 1C),
suggesting that CTD cells were largely enriched. The shRNA
inserts were then amplified from the CTD cells and subjected
to deep sequencing.
The RNAi screening identified 341 candidate genes, each of
whichwas targeted by two ormore small hairpin RNAs (shRNAs),
eliminating the off-target effect of shRNA. Their symbols and
basic information are listed in Table S1.
Analysis and Validation of Screening Results
To characterize the enriched biological processes and pathways
in our screen, the 341 gene hits were subjected to gene ontology
(GO) enrichment analysis and Kyoto Encyclopedia of Genes and
Genomes (KEGG) database analysis (Figures 1D and 1E). The
genes involved in lipid metabolism and intracellular transport
were amply presented, constituting 28.7% of total candidates
(Figures 1D and 1E). Among these hits, there is NPC1, loss of
which is well known to trap cholesterol in lysosome and prevent
cholesterol from traveling to PM. This serves as a positive control
and suggests our screen was successful. Our screen also recov-
ered genes that participate in LDLR expression regulation and
endocytosis, such as SREBP2, SCAP (Brown and Goldstein,
1997), LDLR (Brown and Goldstein, 1986), and AP2 associated
kinase 1 (AAK1) (Conner and Schmid, 2002). Because silencing
of these genes prevents cells from taking up LDL, their appear-
ance in the candidates list was expected.
Unexpectedly, we found marked enrichment for genes
associated with neurological diseases, peroxisome, calcium,
transcription/RNA processing, immune response, cell adhesion,
Hh pathway, ubiquitin-mediated proteolysis, and purine meta-
bolism. It is interesting that neurological disease-related genes
are discovered in our screen to affect cholesterol transport. As
exemplified by NPC disease, which is characterized by severe
neurological symptoms secondary to cholesterol accumulation
in lysosome, the neuron is particularly sensitive to cholesterol
alteration, and impaired cholesterol transport may be a mecha-
nism shared by these neurological diseases.
(D) Bioinformatics classification of the hits into biological processes andmolecular functions categories. The number in the bracket shows the number of genes in
each category.
(E) Statistically enriched biological processes superimposed on a sketch depicting a cell, with the corresponding p value of GO analysis in the screen. Genes in
red refer to representative hits.
See also Figure S1 and Table S1.
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Figure 2. Peroxisome Forms Transient and Dynamic Membrane Contacts with Lysosome
(A) Knockdown of the peroxisome genes identified in the screen led to cholesterol accumulation and decrease of PM cholesterol levels. The ‘‘+’’ indicates the
degree of cholesterol accumulation; the ‘‘’’ indicates no obvious cholesterol accumulation.
(B) SV589 cells transfected with indicated siRNAs were stained with filipin (red) and antibody against endogenous LAMP1 (green) or PMP70 (green). Scale bar,
10 mm. LAMP1: lysosome marker, PMP70: peroxisome marker.
(C) HeLa cells transfected with mouse ABCD1-mCherry were assessed by immunostaining with antibody against PMP70 (green) or LAMP1 (green). Scale bar,
10 mm.
(D) Quantification of colocalization of ABCD1 with organelle-specific markers shown in (C) and Figure S3A. GM130, Golgi marker; EEA1, early endosomemarker.
Data represent mean ± SD (n = 4, 35 cells per independent experiment).
(legend continued on next page)
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To further confirm the hits, we selected 30 representative
genes covering all 14 classes and validated them using distinct
shRNA sequences. The survival rate of knockdown cells is
dramatically higher upon AmB treatment as compared with con-
trol cells (Figure S1D). Among the 30 representative genes, indi-
vidual knockdown of 27 genes caused PM-cholesterol content
to decrease by >50% (Figure S1F). Fifteen genes exhibited
markedly enhanced cholesterol accumulation in cells as shown
by filipin staining (Figure S1G). These results confirmed the reli-
ability of our screen.
Intriguingly, genes encoding peroxisomal proteins were statis-
tically enriched (Figures 1D and 1E). When the peroxisomal hits,
including ABCD1, ACOT8, BAAT, TMEM135, PEX1, PEX3,
PEX6, PEX10, and PEX26 were individually knocked down, the
PM-cholesterol level significantly decreased by 35%–84% as
compared to control (Figure 2A). Cholesterol accumulation was
observed in lysosome, but not peroxisome (Figures 2B and S2B).
Peroxisome Forms Transient and Dynamic Contacts
with Lysosome
How can depletion of peroxisomal proteins lead to cholesterol
accumulation in lysosome? To answer this question, we used
ABCD1, a peroxisomal membrane protein and also one of the
strongest hits from our screen, as a representative to investigate
the mechanism.
ABCD1 mainly colocalized with the peroxisome marker
PMP70 as expected. However, significant amount of colocaliza-
tion between ABCD1 and lysosome marker LAMP1 was surpris-
ingly observed (Figures 2C, 2D, and S3A). Using GM130 as
marker for the Golgi apparatus and EEA1 and Rab5 as early en-
dosome markers, we found the lysosome-peroxisome contact
was very specific as there was little detectable association be-
tween peroxisome and these two organelles (Figures 2D and
S3A). Is the apparent colocalization of lysosome and peroxisome
due to the sporadic distribution of ABCD1 in lysosome? SKL is a
strong peroxisome localization signal and the EGFP-His6-SKL
protein is widely used to label peroxisome. We analyzed other
peroxisome markers such as transfected EGFP-His6-SKL and
endogenous PMP70 to rule out potential interference of partic-
ular marker or antibody and found a similar partial colocalization
between lysosome and peroxisome (Figures S3A–S3C).
We took extra caution to further validate this phenomenon us-
ing 3D reconstitution, super resolution structured illuminationmi-
croscopy (SR-SIM), and electron microscopy. 3D reconstitution
and high resolution confocal images showed that the small
membrane interaction between lysosome and peroxisome could
indeed be observed using different microscopic methods (Fig-
ures 2E and 2F). Moreover, lysosome and peroxisome formed
contacts in primary mouse hepatocytes detected by transmis-
sion electron microscopy (Figure 2G). With these validations,
we named this phenomenon lysosome-peroxisome membrane
contact (LPMC). To our knowledge, the LPMC has not been
reported before.
Time-lapse microscopy was next employed to understand the
LPMC dynamics in living cells. It revealed that the contact be-
tween lysosome and peroxisome was only transient. In a time
frame of a few dozen to 100 s, a particular peroxisome formed
a contact with one lysosome, then was released and moved
away. It could then associated with another lysosome in a similar
time frame (Figure 2H; Movies S1 and S2). Notably, we observed
no fusion of lysosomewith peroxisome (Figure 2H). Consistently,
a lysosomal matrix protein such as NPC2 was not detected in
peroxisome when LPMC formed (Figure S3B).
To further validate the LPMC, we designed an organelle co-
precipitation assay (Figure S3D). The cells stably expressing
EGFP-His6-SKL were lysed without disturbing organelle integ-
rity, and the membrane fractions were incubated with Ni Se-
pharoses to pull down peroxisome. The isolated fractions were
then examined by fluorescent images of Ni Sepharoses and
western blot. As shown in Figure S3E, NPC1-mCherry-labeled
lysosome (red) could be observed on the beads covered by
peroxisome (green). On the other hand, mCherry-Rab5-labeled
early endosome was not co-precipitated suggesting the LPMC
was specific. In line with these results, western blot analysis
showed that the lysosomal protein LAMP1 was efficiently copre-
cipitated with peroxisome, but markers for other organelles were
not (Figure S3F). Together, these lines of evidences strongly
demonstrate the presence of LPMC.
We next examined if LPMC is regulated. Knockdown of NPC1
or ABCD1 significantly decreased the LPMC, with this effect be-
ing evident using both cell imaging and organelle co-precipita-
tion methods (Figures 3A–3C). Depletion of other peroxisomal
functional proteins such as PEX1 also led to less LPMC (Figures
S2B and S2C). More importantly, the LPMC was significantly
reduced under cholesterol depletion status, and this reduction
could be time-dependently reversed by cholesterol repletion
from LDL (Figures 3D–3F). Knockdown of LDLR, Clathrin heavy
chain (CHC), or co-depleting of adaptor proteins genes including
AP2 subunit alpha 2, ARH, and Dab2 to inhibit LDL endocytosis
not only attenuated lysosomal cholesterol replenishment, but
also decreased the LPMC (Figures 3G and 3H). These results
suggest that cellular cholesterol content regulates LPMC, which
also requires proper functions of lysosome and peroxisome.
Synaptotagmin VII Is a Lysosomal Protein Binding
Peroxisome
We next sought to identify the molecules bridging LPMC. A
multi-arm proteomics approach was employed to analyze lyso-
somal membrane proteins, peroxisomal proteins, and NPC1
interacting proteins (Figures S4A and S4B; Table S2). After merg-
ing of the protein lists, candidates involved in vesicle fusion or
organelle dynamics were selected as refined candidates for
(E) A representative SR-SIM image of the overlaid endogenous LAMP1 (green) and PMP70 (red) images. Arrowheads indicate LPMC sites. Scale bar, 10 mm.
(F) HeLa cells were immunostained with antibodies against LAMP1 and PMP70 and analyzed by Volocity-3D software. Arrowheads indicate LPMC sites. Scale
bar, 10 mm.
(G) Transmission electron micrograph of the LPMC in a mouse liver cell. L, lysosome, P, peroxisome. Scale bar, 500 nm.
(H) SV589 cells were transfected with EGFP-SKL and NPC1-mCherry. Time-lapse images were acquired. Scale bar, 500 nm. See also Movie S2.
See also Figures S2 and S3 and Movies S1 and S2.
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Figure 3. Regulation of Lysosome-Peroxisome Membrane Contacts
(A) SV589 cells were transfected with indicated siRNAs and immunostained with antibodies against LAMP1 (green) and PMP70 (red). Scale bar, 10 mm.
(B) Quantification of LPMC in (A). Data represent mean ± SD. **p < 0.01, one-way ANOVA (n = 4, 35 cells per independent experiment).
(C) Lysosome-peroxisome association revealed by organelle co-precipitation assay.
(legend continued on next page)
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RNAi validation (Table S2). Out of the 16 candidates, Synapto-
tagmin VII (Syt7) was the only that passed the validation: its
knockdown but not that of others caused clear cholesterol accu-
mulation in cells (Figure S4C).
Synaptotagmin is a family of proteins involving in vesicle
interaction and fusion. Syt7 is widely expressed and plays
important role in lysosomal exocytosis, membrane resealing,
and wound healing (Andrews and Chakrabarti, 2005). Syt7
mainly colocalized with the lysosome marker LAMP1 (Fig-
ure 4A). Similarly to NPC1 and LAMP1, Syt7 significantly colo-
calized with the peroxisome marker PMP70 but not markers
for Golgi or early endosome (Figures 4A and 4B). Knockdown
of Syt7 resulted in cholesterol accumulation in lysosome
(Figure 4C), and the LPMC was also dramatically diminished
(Figure 4D). Syt7 is a transmembrane protein with a short N-ter-
minal ectodomain, a single transmembrane segment, and a
large cytosolic region containing two tandem Ca2+-binding C2
domains (C2A and C2B, Figure 4E). The C2A and C2B domains
are responsible for the Ca2+-dependent interactions between
Syt7 and SNAREs or phospholipids. When overexpressed,
these domains compete for binding to SNAREs or phospho-
lipids and function as dominant-negative forms (Desai et al.,
2000). We utilized a similar method and found that overexpres-
sion of C2A or C2B domain dramatically inhibited LPMC in cell
imaging and organelle coimmunoprecipitation (coIP) (Figures
4F, 4G, and S4D), accompanied by cholesterol accumulation
in cells (Figure 4H).
We further developed an in vitro reconstitution assay to
dissect the mechanism of LPMC (Figure S5A). Briefly, EGFP-
His6-SKL-labeled peroxisome and NPC1-FLAG-mCherry-
labeled lysosome were separately isolated by density gradient
centrifugation. The peroxisomes were further precipitated by
Ni Sepharoses and incubated with purified lysosome fractions.
After incubation, Ni Sepharoses were separated by centrifuga-
tion and subjected to confocal microscopy and western blot.
As shown in Figure S5B, lysosome labeled as red was pulled
down with peroxisome in the presence of cytosol and ATP/
GTP. Consistently, the lysosome marker NPC1-FLAG-mCherry
was co-precipitated at this condition (Figure 4I). These results
suggest energy and some cytosolic proteins may facilitate
LPMC. Addition of dominant-negative Syt7-C2AB protein (Fig-
ure S5C) in the incubation step blocked the lysosome peroxi-
some interaction (Figures 4J and S5D). Similarly, when lyso-
somes from Syt7 or NPC1 RNAi-depleted cells were incubated
with control peroxisome, the LPMC was significantly reduced.
Conversely, when lysosome from control cells was incubated
with peroxisome from Syt7 or NPC1 RNAi-depleted cells, the
LPMC was not affected (Figures 4K and S5E). These findings
indicate Syt7 is a lysosomal protein required for LPMC
formation.
PI(4,5)P2 in Peroxisome Membrane Bridges LPMC
It has been documented that SNAREs mediate membrane con-
tacts and fusion throughout the secretory pathway (Chen and
Scheller, 2001; Weber et al., 1998). Organelles such as Golgi,
ER, and lysosome are all maintained by SNARE-based fusion
events. However, so far, no peroxisomal SNARE protein has
been identified. Consistent with previous studies (Matsumoto
et al., 2003), no SNARE family protein was identified in our perox-
isomal proteomics (Table S2). Because Syt7 binds to phospho-
lipids besides SNARE, we hypothesized that Syt7-mediated
LPMC might be through its interaction with peroxisomal phos-
pholipids. To test this hypothesis, we examined the binding
specificity of Syt7-C2AB to various phospholipids in a PIP-strip
assay. Syt7-C2AB mainly bound PI(4,5)P2 and to a much lesser
extent PI(5)P and PS; no signal was observed for other phospho-
lipids (Figure 5A). It has been reported that peroxisome can
synthesize significant amounts of PIP2 including PI(4,5)P2 (Jey-
nov et al., 2006). To further validate Syt7-PI(4,5)P2 interaction
under a more relevant format, we performed the liposome flota-
tion assay using liposomesmimicking phospholipid composition
of the mammalian peroxisome membrane (PC:PE:PI:PS =
54:36:5:5) (Hardeman et al., 1990). As shown in Figure 5B,
when mixed with blank liposomes or PI5P containing liposomes,
the His6-C2AB protein was predominantly detected in the
bottom fraction. Trace amount of His6-C2AB in middle and top
fractions was also detected, possible due to the weak binding
of C2AB to PS and PI5P. In contrast, the majority of His6-C2AB
protein was co-floated with liposomes containing PI(4,5)P2 to
the top fraction. These results demonstrated that the C2AB
domain of Syt7 interacts with PI(4,5)P2 in membrane.
Next, we sought to determine whether the Syt7-PI(4,5)P2 inter-
action functions to bridge LPMC using an inducible FKBP12-
FRB heterodimerization system to deplete PI(4,5)P2 on peroxi-
some (Figure 5C). In the constructed SV589 cells, FKBP12 was
targeted to peroxisome by fusion with PEX-mCherry, and the
inositol polyphosphate 5-phosphatase synaptojanin 2 (SYNJ2)
was kept in cytoplasm fused with mCitrine-FRB. Application of
the chemical inducer rapamycin led to peroxisome membrane
recruitment of mCitrine-FRB-SYNJ2 by binding PEX-mCherry-
FKBP12 (Kapitein et al., 2010), which rapidly and irreversibly
converted PI(4,5)P2 to PI(4)P (Figures 5C and 5D). As shown in
Figures 5E and 5F, rapamycin treatment caused a significant
decrease of LPMC and cellular cholesterol accumulation. The
cell expressing only mCitrine-FRB was a control showing no
change of LPMC or cholesterol aggregation. Although cellular
PI(4,5)P2 also presents on PM, depletion of PI(4,5)P2 in PM by
a similar strategy did not decrease LPMC or cause cholesterol
accumulation (Figures S6A–S6C). Furthermore, anti-PI(4,5)P2
antibody specifically reduced the association between lysosome
and peroxisome in vitro (Figures 5G, 5H, and S5F). Together,
(D) HeLa cells were incubated in cholesterol-depleting medium for 16 hr and then refed with LDL for different time durations. Cells were stained with filipin (gray)
and antibodies against LAMP1 (red) and PMP70 (green). Scale bar, 2 mm.
(E) Quantification of LPMC in (D). Data represent mean ± SD (n = 4, 35 cells per independent experiment). **p < 0.01, *p < 0.05.
(F) Organelle co-precipitation assay was performed to validate LPMC when cells were grown under conditions shown in (D).
(G) SV589 cells transfected with indicated siRNAs were stained with filipin (gray) and antibodies against LAMP1 (red) and PMP70 (green). Scale bar, 2 mm.
(H) Quantification of LPMC in (G). Data represent mean ± SD (n = 4, 35 cells per independent experiment). **p < 0.01.
See also Figure S3.
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Figure 4. Synaptotagmin VII Is a Lysosomal Protein Bridging LPMC
(A) SV589 cells transfected with Syt7-mCherry were assessed by immunostaining with indicated antibodies. Scale bar, 2 mm.
(B) Quantification of Syt7 colocalization with organelle-specific markers. Data represent mean ± SD (n = 4, 35 cells per independent experiment).
(legend continued on next page)
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these data demonstrate that PI(4,5)P2 in peroxisome membrane
is required for LPMC and proper cholesterol transport.
Because PI(4,5)P2 is critical for LPMC, we reasoned that the
peroxisome genes from our screen might affect peroxisomal
PI(4,5)P2 level either directly or indirectly. Indeed, a pronounced
decrease in the amount of PI(4,5)P2 in peroxisomal lipid extrac-
tion was detected using dot blots with anti-PI(4,5)P2 antibody
after knocking down ABCD1 or other peroxisomal hits (Fig-
ure S6D). These data suggest that the nine peroxisome proteins
may not directly bind Syt7 but rather influence peroxisomal
PI(4,5)P2 level thereby affecting lysosome association.
Cholesterol Transport through LPMC
To monitor cholesterol transport directly, we used 3H-
cholesterol in the in vitro reconstitution assay (Figure 6A). Briefly,
3H-cholesterol-labeled lysosome was isolated by density centri-
fugation from HEK293T cell pre-incubated with 3H-cholesterol.
Peroxisome was purified from unlabeled cells. The lysosome
and peroxisome were then applied to the in vitro reconstitution
system. After incubation, EGTA washing was performed to
dissociate lysosome from peroxisome while leaving the peroxi-
some on Ni Sepharoses. The 3H-cholesterol in peroxisome
was then measured. To control the specificity, antibodies
against PI(4,5)P2 or unrelated IgG were applied. The
3H-choles-
terol in peroxisome increased in a time-dependent manner and
this increase was blocked by anti-PI(4,5)P2 antibody (Figures
6B and S7A). In addition, lysosomes prepared from NPC1 or
Syt7 RNAi cells failed to support cholesterol transfer to peroxi-
some (Figure 6C), because LPMC did not form when NPC1 or
Syt7 was depleted from lysosome (Figures 4K and S5E). These
data demonstrate that cholesterol can transfer from lysosome
to peroxisome depending on LPMC in vitro.
What about in cells? We performed confocal microscopy on
HeLa cells refed with LDL and observed a time-dependent in-
crease of co-localization between peroxisome and cholesterol
(Figures S7B and S7C). We also directly measured the choles-
terol level in isolated lysosome and peroxisome after incubation
with 3H-cholesteryl oleate containing LDL (scheme in Fig-
ure S7D). The lysosome and peroxisome were both labeled by
3H-cholesterol although peroxisome label was less (Figure 6D).
Results from western blot of organelle markers excluded the
contamination with other organelles (Figure S7E). Furthermore,
knockdown of NPC1 or ABCD1 caused significant increase of
3H-cholesterol in lysosome and decrease in peroxisome (Fig-
ure 6D). LDL pulse chase experiment (Figure S7F) followed by
SR-SIM microscopy showed that there was overlay of peroxi-
some with cholesterol-loaded lysosome, or cholesterol (Fig-
ure S7G). These data suggest cholesterol flows from lysosome
to peroxisome in cells.
To further investigate whether LPMC is required for LDL-
cholesterol transport to the ER, we performed SREBP cleavage
and cholesterol esterification assays because it is well estab-
lished that cholesterol derived from LDL prevents SREBP pro-
cessing and stimulates cholesterol esterification once it reaches
the ER. The results showed that LDL-cholesterol could efficiently
block SREBP processing (Figure 6E) and stimulate cholesterol
esterification (Figure 6F) in control cells. However, these effects
were markedly blunted inNPC1, ABCD1, or Syt7 RNAi cells (Fig-
ures 6E and 6F); demonstrating that cholesterol transport to ER
was largely impaired when LPMC was disrupted.
With the current data and information from previous reports
(Kwon et al., 2009), we propose the below model for cholesterol
transport from lysosome to peroxisome. After internalization,
LDL particles are delivered to lysosome where LDL-containing
cholesteryl ester is hydrolyzed to unesterified cholesterol. The
luminal NPC2 protein binds free cholesterol with the 8-carbon
isooctyl side chain buried within the binding pocket and hands
over the cholesterol molecule to the N-terminal domain of
NPC1. The NPC1-N-terminal domain can penetrate the glycoca-
lyx and facilitate cholesterol to insert into the lysosomal
membrane. Lysosome and peroxisome form close membrane
contacts through interaction between Syt7 and PI(4,5)P2. Thus,
cholesterol can move from lysosome to peroxisome (Figure 6G).
Intracellular Cholesterol Accumulation in Peroxisomal
Disorders
ABCD1mutation causes X-ALD, which is a neurological disease
with progressive CNS demyelination and adrenal insufficiency
(Forss-Petter et al., 1997). X-ALD is one of the prevalent peroxi-
somal disorders and there is no effective treatment (Moser et al.,
2005). Our work has demonstrated cholesterol transports from
lysosome to peroxisome through LPMC, and ABCD1 depletion
impairs LPMC and leads to cholesterol accumulation. However,
there is no previous report on cholesterol transport defect in
(C) SV589 cells transfected with indicated siRNAs were stained with filipin (gray) and antibodies against LAMP1 (green) and PMP70 (red). Insets show high
magnification of the areas framed by a white box. Scale bar, 10 mm.
(D) Quantification of LPMC in (C). Data represent mean ± SD (n = 4, 35 cells per independent experiment). **p < 0.01.
(E) Domain structure of the Syt7 protein.
(F) SV589 cells transfected with mCherry, Syt7, C2A, or C2B of Syt7 were assessed by immunostaining with antibodies against LAMP1 and PMP70. Shown is the
quantification of LPMC. Data represent mean ± SD (n = 4, 30 cells per independent experiment). NS, not significant, **p < 0.01. The fluorescence images of cells
are shown in Figure S4D.
(G) HeLa/EGFP-His6-SKL cells were transfected with the indicated plasmids and the lysosome-peroxisome association was analyzed by organelle co-precip-
itation assay.
(H) SV589 cells transfected with the indicated plasmids were stained with filipin (gray). Arrowheads indicate the cells expressing Syt7 or Syt7 variants (magenta).
Scale bar, 10 mm.
(I) In vitro reconstitution of LPMC. The images of Ni Sepharoses are shown in Figure S5B.
(J) Recombinant GST or Syt7-C2AB protein was applied in the in vitro reconstitution system. The images of Ni Sepharoses are shown in Figure S5D.
(K) Lysosome or peroxisome was purified from cells transfected with indicated siRNAs and then used for the in vitro reconstitution assay. The images of Ni
Sepharoses are shown in Figure S5E. Ctr, control.
See also Figures S4 and S5 and Table S2.
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Figure 5. PI(4,5)P2 of Peroxisome Is Required for LPMC
(A) Protein-lipid overlay. A scheme of the PIP-strip membrane is shown (left). Arrowheads indicate specific lipids binding. Red lines highlight the phospholipid
species.
(legend continued on next page)
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X-ALD or any other peroxisomal disorders. Therefore, we sought
to validate our findings in vivo by examining if there is cholesterol
accumulation in ABCD1 knockout (KO) animal models and
fibroblasts of human patients with different types of peroxisomal
disorders.
As shown in Figure 7A, cholesterol accumulated in zebrafish
embryo cells injected with morpholino antisense oligomer (MO)
againstNPC1 orABCD1. Furthermore, cholesterol accumulation
was observed in fibroblasts, cerebellum, and adrenal gland of
ABCD1 KO mice (Figures 7B and 7C), a well-accepted animal
model capturing the pathological characteristics of X-ALD. Inter-
estingly, in the adrenal gland cholesterol deposits were located
almost exclusively in the cortex but not in themedulla (Figure 7C),
correlating with ABCD1’s specific expression in the cortex
(Troffer-Charlier et al., 1998).
Because it is known that the ABCD1 KO mice do not show an
abnormal behavioral or neurological phenotype up to 15months,
we analyzed the behavioral deficits associated with CNS demy-
elination using rotarod test at the ageof 7 and 20months, respec-
tively. When compared with WT littermates, the 20-month-old
ABCD1 KO mice displayed a marked impairment (19%) in their
ability to stay on top of a rotated cylinder during 2 days trial, while
the 7-month-old ABCD1 KO mice were not affected (Figure 7D).
Open field mobility paradigm was also used to study sponta-
neous locomotion and exploratory behavior. As shown in Figures
7E and 7F, the 20-month-old ABCD1 KO mice exhibited signifi-
cantly fewer numbers of rearings and traveled shorter distances
in comparison with WT mice or 7-month-old ABCD1 KO mice.
This is important because the cholesterol accumulation occurs
as early as 7 months (Figure 7C), long before the manifestation
of the neurological phenotypes (20-month-old), suggesting not
only that losing of ABCD1 leads to cholesterol trafficking defects,
but also that intracellular cholesterol accumulation might be a
mechanism causing X-ALD symptoms.
To further evaluate the role of peroxisome in cholesterol
trafficking, cultured fibroblasts from patients with X-ALD, or
two peroxisome biogenesis disorders Infantile Refsum disease
(IRD) and Zellweger syndrome (ZS) were used for cholesterol
staining. As shown in Figure 7G, drastic cholesterol accumula-
tion was observed in these fibroblasts, suggesting peroxisome
plays an essential role in intracellular cholesterol transport.
DISCUSSION
Using an elegantly designed cellular system, our genome-wide
shRNA screen allows a comprehensive dissection of the genes
and pathways that may regulate intracellular cholesterol trans-
port. Besides the previously known cholesterol transport gene
like NPC1, we uncovered over 300 additional genes, among
which the genes encoding peroxisomal proteins were highly
enriched.
We showed that peroxisome played an essential role in intra-
cellular cholesterol transport through forming membrane con-
tacts with lysosome. We provided multiple lines of evidence to
solidify this observation. First, LPMC was observed by confocal
microscopy and decreased by cholesterol depletion and knock-
ing down of NPC1 or ABCD1. Second, super resolution micro-
scopy showed the overlapping signals between peroxisome
and lysosome (Figure 2E). Third, 3D reconstitution verified
LPMC from different angles (Figure 2F). Fourth, transmission
electron micrographs directly observed LPMC in primary mouse
hepatocytes (Figure 2G). Fifth, time-lapse imaging showed the
LPMC is dynamic in living cells (Figure 2H). Sixth, organelle co-
precipitation assay detected the physical interaction between
peroxisomes and lysosomes (Figures 3C and S3F). Seventh,
in vitro reconstitution assay confirmed that lysosome and perox-
isome can form contacts specifically (Figures 4I and S5).
As for the molecules bridging LPMC, our data demonstrate
lysosomal protein Syt7 binds peroxisomal lipid PI(4,5)P2 to
form a transient contact. How are Syt7 activation and peroxi-
somal PI(4,5)P2 level regulated? It is well known that calcium
can bind Syt7 leading to a conformational change (Fukuda and
Mikoshiba, 2001). Meanwhile, the level of PI(4,5)P2 can be
modulated by phosphatidylinositol kinases and phosphatases.
Its distribution is also under dynamic regulation. Therefore,
how different proteins/pathways regulate Syt7 and PI(4,5)P2
and then influence LPMCand cholesterol transport is a particular
interesting subject for further exploration. The in vitro reconstitu-
tion assay developed in this study would be a powerful tool. Our
screen discovered 9 peroxisomal proteins including ABCD1,
knockdown of which individually leads to lowered peroxisomal
PI(4,5)P2 level (Figure S6D). These nine peroxisomal proteins
cover different functions and are all required for proper peroxi-
somal function. Therefore, the dysfunction of peroxisome may
underlie the decrease of PI(4,5)P2 and LPMC. Further studies
are still needed to understand how these peroxisome proteins
are functionally connected to PI(4,5)P2 regulation.
Previous studies have indicated that cholesterol can leave lyso-
some by vesicular or non-vesicular transport. Urano et al. (2008)
showed that LDL-cholesterol can be transported from L/L to the
trans-Golgi network through vesicular trafficking. Du et al.
(2011) reported that ORP5, an oxysterol-binding protein-related
(B) B0: workflow of the liposome flotation assay. B0 0: the presence of recombinant proteins in the top (T), middle (M), and bottom (B) fractions were detected by
western blot using anti-His6 antibody. B
0 0 0: semiquantitative densitometric analysis of western blot in B0 0. The amount of liposomes-associated proteins was
determined by comparing proteins present in the top fraction to the total amount of proteins present in the top, middle, and bottom fractions.
(C) Schematic representation of the rapamycin-inducible heterodimerization system used to recruit SYNJ2 to the peroxisome membrane.
(D) Validation of the rapamycin-inducible system in SV589 cells. Scale bar, 10 mm.
(E) SV589 cells were transfected with PEX-mCherry-FKBP12 together with either mCitrine-FRB or mCitrine-FRB-SYNJ2. Cells were then treated with rapamycin,
stained with filipin (gray), and immunostained with antibody against LAMP1, followed by Cy5-conjugated anti-mouse secondary antibody (pseudocolor, red).
Scale bar, 2 mm.
(F) Quantification of LPMC in (E). Data represent mean ± SD (n = 4, 30 cells per independent experiment). NS, not significant, **p < 0.01.
(G) Anti-PI(4,5)P2 or control IgG was applied in the in vitro reconstitution system. The images of Ni Sepharoses are shown in Figure S5F.
(H) Semiquantitative densitometric analyses of (G).
See also Figures S5 and S6.
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protein, may mediate cholesterol efflux from lysosome to ER
through binding cholesterol and NPC1. Here, cholesterol trans-
port across LPMC is another mechanism for cholesterol efflux
from lysosome. Disruption of LPMC by different means causes
significant lysosomal cholesterol accumulation. X-ALD animal
models and fibroblasts of human patients with different types of
peroxisomal disorders displayed drastic cholesterol accumula-
tion (Figure 7), suggesting LPMC is a major route for cholesterol
to leave the lysosomal membrane. Our in vitro reconstitution
assay suggests cytosol may facilitate cholesterol movement
from lysosome to peroxisome (Figure 4I). Finally, it is possible
that cytosolic cholesterol binding proteins such as StarD4 and
ORPs may accelerate the cholesterol movement from lysosomal
membrane to peroxisome when LPMC forms.
After reaching peroxisome, the cholesterol might be further
oxidized or participate in bile acid synthesis in peroxisome.
Cholesterol is also required for peroxisome lipid raft assembly
and peroxisome biogenesis (van der Zand and Tabak, 2013;
Woudenberg et al., 2010), and we estimated peroxisome con-
tains5%of total cellular cholesterol (data not shown). Because
disrupting LPMC decreases PM cholesterol level (Figure 2A) and
impairs LDL-cholesterol reaching the ER (Figures 6E and 6F), it is
likely that peroxisome may associate with other organelles and
deliver cholesterol to them. This notion is further supported
by the observation that cholesterol in lysosome increased by
20%–40% whereas cholesterol in peroxisome only decreased
by 2% after LPMC disruption in cells (Figure 6D). Alternatively,
cholesterol transport via LPMC may be tightly coupled with
cholesterol modification including oxidation and esterification.
It is interesting to further study how cholesterol transportation
is affected by cholesterol modification and vice versa. Besides
cholesterol transfer, LPMC may regulate other functions of lyso-
some and peroxisome, such as autophagy, mTOR signaling, and
peroxisome biogenesis.
Dramatic cholesterol accumulation was observed in X-ALD
animal models and human patients’ fibroblasts with mutations
in different peroxisomal genes (Figure 7). Notably, the choles-
terol accumulation (7-month-old) occurs long before the
manifestation of the neurological phenotypes (20-month-old),
suggesting intracellular cholesterol accumulation might be a
potential mechanism causing X-ALD symptoms. It was also
noted that although there was early onset of very long chain fatty
acid accumulation, relief of its accumulation did not significantly
improve the disease symptoms (Prieto Tenreiro et al., 2013). On
the other hand, it was well established that the accumulation of
cholesterol in NPC disease patients is the cause of neuron death
and neurological phenotypes. Mobilizing cholesterol by cyclo-
dextrin constitutes a beneficial treatment for NPC patients (Liu
et al., 2010). Therefore, the cholesterol trafficking blockage
may underlie the pathological mechanism of peroxisome disor-
ders, which could provide novel strategies for diagnosis and
treatment of these diseases.
In summary, through functional genome-wide RNAi screen
and hits analysis, we demonstrate the existence of lysosome-
peroxisome membrane contacts mediated by Syt7- PI(4,5)P2
binding, through which cholesterol is transported from lysosome
to peroxisome. Peroxisomal disorders display significant intra-
cellular cholesterol accumulation prior to neuronal symptoms.
Together, this study suggests a central role of peroxisome in
intracellular cholesterol trafficking and highlights the clinical rele-
vance of cholesterol transport in peroxisomal disorders.
EXPERIMENTAL PROCEDURES
Materials and plasmids, cell culture, growth assay, liposome flotation assay,
and other procedures are described in the Extended Experimental
Procedures.
shRNA Screen and Analysis
HeLa cells were infected with the MISSION LentiPlex human pooled shRNA
library consists of over 75,000 shRNA constructs from the TRC collection tar-
geting 15,000+ human genes. Infected cells were selected with puromycin
(2 mg/ml) for 4 days. After five rounds of AmB selections (Extended Experi-
mental Procedures), survived populations were collected, and shRNA inserts
were amplified from genomic DNA by PCR. PCR products were sequenced
by deep-sequencing. All the deep sequencing data were log10 transformed
and normalized to standard derivation from the screen-wide mean, which
depicted as Z score [Z = (gene’s deep sequencing score – average deep
sequencing score)/screen standard derivation]. Z score equal to 1.96 (p =
0.05) was used as cut-off value to determine the screen hits. Genes with
Z score over 1.96 (p < 0.05) or targeted by five independent shRNAs were
considered as screen hits.
Organelle Co-Precipitation Assay
Triplicate samples for each treatment were homogenized in extraction buffer
(5 mM MOPS [pH 7.65], with 0.25 M sucrose, 1 mM EDTA, 0.1% ethanol
and protease inhibitors) and centrifuged at 1,0003 g for 10 min. Supernatants
Figure 6. Transfer of 3H-Cholesterol from Lysosome to Peroxisome
(A) Outline of the in vitro 3H-cholesterol transfer assay.
(B) Ni Sepharoses bound-peroxisome was preincubated with anti-PI(4,5)P2 or control IgG and then used for the in vitro
3H-cholesterol transfer assay. Values are
expressed as the percentage of 3H-cholesterol in lysosome prior to reaction and presented as the mean ± SD of three independent repeats of experiments.
**p < 0.01.
(C) Radiolabeled lysosomes were isolated from cells transfected with indicated siRNAs. Peroxisome was purified from wild-type cells and were then used for the
in vitro 3H-cholesterol transfer assay as in (A). Data are presented as the mean ± SD of three independent repeats of the experiments. **p < 0.01.
(D) HEK293T cells transfected with indicated siRNAs were depleted of cholesterol and then pulsed with 3H-cholesteryl oleate-LDL for 3 hr. Then, lysosome and
peroxisomewere purified separately and the 3H-cholesterol weremeasured. Values are expressed as percentage of control lysosome and presented as themean
± SD of three independent experiments. *p < 0.05, **p < 0.01.
(E) HeLa cells transfected with indicated siRNAs were subjected to analysis of SREBP-2 cleavage. pSREBP2, precursor of SREBP2; nSREBP2, nuclear form of
SREBP2; CHC, clathrin heavy chain. *Indicates the nonspecific band.
(F) HeLa cells transfected with the indicated siRNAs were subjected to cholesterol esterification assay. TG, triacylglycerol. Quantification of cholesteryl [14C]-
esters was analyzed by Image J. NS, not significant, **p < 0.01.
(G) A working mechanism of LDL-derived cholesterol transport out of lysosome.
See also Figure S7.
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Figure 7. Cholesterol Accumulation in Animals and Human Patients with Peroxisomal Disorders
(A) Filipin staining of unesterified cholesterol in zebrafish embryos. Scale bar, 10 mm.
(B) Filipin staining of the tail-tip fibroblast cells from the mice at the age of 7 months (n = 4 per group). Scale bar, 10 mm.
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were incubated with Ni Sepharoses at 4C rotating for 2 hr. Beads were
washed five times with extraction buffer. Then, 1 ml Ni Sepharoses were
mounted and analyzed by confocal microscope. Proteins bound to Sepharo-
ses were eluted and subjected to western blot.
In Vitro Reconstitution Assay
EGFP-His6-SKL-labeled peroxisome and NPC1-FLAG-mCherry-labeled lyso-
some were first isolated by iodixanol density gradient centrifugation, respec-
tively. The lysosome fractions were diluted with reconstitution buffer
(250 mM sucrose, 1 mM DTT, 1 mM MgCl2, 50 mM KCl, and 20 mM HEPES
[pH 7.2]), precipitated at 28,000 3 g for 30 min and resuspended in reconsti-
tution buffer. The peroxisome fractions were incubated with Ni Sepharoses,
washed with reconstitution buffer plus 2 mM EGTA for four times, and then
incubated with lysosome in the presence or absence of 1 mg/ml cytosol,
1 mM ATP, 1 mM GTP, and ATP-regenerating system (30 mM creatine phos-
phate, 0.05 mg/ml creatine kinase) at 37C for 30 min. If needed, anti-PI(4,5)P2
and Syt7-C2AB protein were applied 10min at 4C before the addition of ATP-
regenerating system and cytosol. Ni Sepharoses were spun down, washed
with reconstitution buffer, and subjected to microscopy and western blot.
In Vitro 3H-Cholesterol Transfer Assay
Cells were incubated with 1 mCi/ml 3H-cholesterol in growth medium over-
night. The cells were then washed with PBS containing 0.2% BSA twice.
The 3H-cholesterol-labeled lysosome was isolated and its content of 3H-
cholesterol was measured using liquid scintillation. Peroxisome was purified
from unlabeled cells by aforementioned method. The peroxisome and 3H-
cholesterol-labeled lysosome were subjected to in vitro reconstitution assay
as described above. After incubation for different time durations at 37C, the
samples were spun down and lysosome was washed off by washing with
reconstitution buffer plus 2 mM EGTA for four times. The 3H-cholesterol on
Ni Sepharoses bound-peroxisome was measured by liquid scintillation. The
3H-cholesterol content in peroxisome was then normalized to the total input
3H-cholesterol content of lysosome prior to reaction and was expressed as
a percentage.
Measurement of LDL-Derived 3H-Cholesterol in Lysosome and
Peroxisome
After transfected with the indicated siRNAs, HEK293T cells were cultured in
cholesterol-depleting medium for 16 hr and incubated with 3H-cholesteryl
oleate-LDL for 3 hr at 37C. Then the cells were washed with PBS containing
0.2% BSA twice. Lysosome or peroxisome fractions were isolated by density
gradient centrifugation separately and analyzed in a liquid scintillation
counting.
Animals and Treatment
All animals were maintained and used in accordance with the guidelines of the
Institutional Animal Care andUseCommittee of the Shanghai Institutes for Bio-
logical Sciences. Mice were treated as described in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, two tables, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.02.019.
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